"10.1371_journal.pone.0078154","plos one","2013-10-22T00:00:00Z","James L Trevaskis; Christine M Mack; Chengzao Sun; Christopher J Soares; Lawrence J Dâ€™Souza; Odile E Levy; Diane Y Lewis; Carolyn M Jodka; Krystyna Tatarkiewicz; Bronislava Gedulin; Swati Gupta; Carrie Wittmer; Michael Hanley; Bruce Forood; David G Parkes; Soumitra S Ghosh","Amylin Pharmaceuticals LLC, San Diego, California, United States of America","Conceived and designed the experiments: JLT CMM CS CJS LJD OEL CMJ KT MH BF DGP SSG. Performed the experiments: JLT CS LJD DYL KT BG SG CW. Analyzed the data: JLT CMM CS LJD CMJ KT BG SG. Wrote the manuscript: JLT CS DGP SSG.","This research was entirely funded by Amylin Pharmaceuticals, LLC. All authors were employed by and were shareholders in Amylin Pharmaceuticals during the study period. Patents filed or issued: United States Patent No 8,076,288, (Hybrid polypeptides having glucose lowering activity). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","10","James L Trevaskis","JLT",16,TRUE,12,8,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
